Drug Profile

FOV 407

Alternative Names: EXN-407; FOV-407

Latest Information Update: 03 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Exonate
Developer Foventa Therapeutics
Class Eye disorder therapies; Small molecules
Mechanism of Action SRPK1 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Diabetic macular oedema
No development reported Wet age-related macular degeneration

Most Recent Events

01 Sep 2026 Exonate is now called Foventa Therapeutics
29 Jul 2025 Exonate plans the phase IIb CLEAR-DE trial for Diabetic retinopathy in Australia, Middle East and China (Opthalmic) in 2026
29 Jul 2025 Adverse events data from a phase Ib/IIa trial in Diabetic macular oedema released by Exonate

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com